Home » News » Long-Term Benefits of Anti-CD20 Drugs in Relapsing MS

Long-Term Benefits of Anti-CD20 Drugs in Relapsing MS

Long-Term Benefits of Anti-CD20 Drugs in Relapsing MS
May Be Interested In:Not Even Biden’s Own Staff Knew How Badly He Was Declining



(MedPage Today) — B-cell therapy for multiple sclerosis (MS) was first approved in 2017, after the anti-CD20 agent ocrelizumab (Ocrevus) demonstrated its ability to strongly suppress the acute inflammatory activity and MRI lesions associated with…

share Share facebook pinterest whatsapp x print

Similar Content

How to Hurt Myanmar's Coup Leaders, According to Activists
How to Hurt Myanmar’s Coup Leaders, According to Activists February 1, 2022
Assassin's Creed-maker Ubisoft gets $1.25bn investment from Chinese tech giant Tencent
Assassin’s Creed-maker Ubisoft gets $1.25bn investment from Chinese tech giant Tencent March 28, 2025
Battu par le match du Canadien, le débat des chefs rejoint une moyenne de 805 000 curieux à Radio-Canada
Battu par le match du Canadien, le débat des chefs rejoint une moyenne de 805 000 curieux à Radio-Canada April 17, 2025
Ivan Hancko
What’s the Best First Sex Toy for You? Top Recommendations and Why They Work – Chart Attack February 20, 2025
Switch 2 hands on: Mario Kart World, Donkey Kong, Joy-Con
Switch 2 hands on: Mario Kart World, Donkey Kong, Joy-Con April 3, 2025
Danielle Smith.
Smith rolls out ‘buy Canadian’ plan in response to Trump tariffs March 5, 2025
▲
Daily Dispatch: The Headlines You Can’t Ignore | © 2025 | Daily News